Advances in diagnostic radiology

Investigative Radiology

Volumn 45, Issue 12, 2010, Pages 823-826

  Runge, Val M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Computed tomography; Contrast media; Magnetic resonance

Indexed keywords

CONTRAST MEDIUM; GADODIAMIDE; GADOLINIUM CHELATE; GADOVERSETAMIDE;

AORTA GRAFT; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CANCER SCREENING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DUAL ENERGY COMPUTED TOMOGRAPHY; HIGH RISK PATIENT; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAMMOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REVIEW; STENT; ULTRASOUND; WHOLE BODY MRI; WHOLE BODY PET;

EID: 78650677821     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31820244fa     Document Type: Review

References (96)

1. Schindera ST, Graca P, Patak MA, et al. Thoracoabdominal-aortoiliac multidetector- row CT angiography at 80 and 100 kVp: assessment of image quality and radiation dose. Invest Radiol. 2009;44:650-655.
2. Szucs-Farkas Z, Schaller C, Bensler S, et al. Detection of pulmonary emboli with CT angiography at reduced radiation exposure and contrast material volume: comparison of 80 kVp and 120 kVp protocols in a matched cohort. Invest Radiol. 2009;44:793-799.
3. Prakash P, Kalra MK, Kambadakone AK, et al. Reducing abdominal CT radiation dose with adaptive statistical iterative reconstruction technique. Invest Radiol. 2010;45:202-210.
4. Voth M, Haneder S, Huck K, et al. Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/ kg) of gadobutrol at 3.0 T. Invest Radiol. 2009;44:627-633.
5. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusionweighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol. 2009;44:683-690.
6. Weckbach S, Findeisen HM, Schoenberg SO, et al. Systemic cardiovascular complications in patients with long-standing diabetes mellitus: comprehensive assessment with whole-body magnetic resonance imaging/magnetic resonance angiography. Invest Radiol. 2009;44:242-250.
7. Ludescher B, Machann J, Eschweiler GW, et al. Correlation of fat distribution in whole body MRI with generally used anthropometric data. Invest Radiol. 2009;44:712-719.
8. Boss A, Kolb A, Hofmann M, et al. Diffusion tensor imaging in a human PET/MR hybrid system. Invest Radiol. 2010;45:270-274.
9. Reichardt W, Juettner E, Uhl M, et al. Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. Invest Radiol. 2009;44:298-303.
10. Lemke A, Laun FB, Klau M, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol. 2009;44:769-775.
11. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol. 2010;45:15-23.
12. Takahara T, Kwee TC, van Leeuwen MS, et al. Diffusion-weighted magnetic resonance imaging of the liver using tracking only navigator echo: feasibility study. Invest Radiol. 2010;45:57-63.
13. Dale BM, Braithwaite AC, Boll DT, et al. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol. 2010;45: 104-108.
14. Notohamiprodjo M, Dietrich O, Horger W, et al. Diffusion tensor imaging (DTI) of the kidney at 3 Tesla-feasibility, protocol evaluation and comparison to 1.5 Tesla. Invest Radiol. 2010;45:245-254.
15. Prompona M, Cyran C, Nikolaou K, et al. Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. Invest Radiol. 2009;44:369-374.
16. Roes SD, Hammer S, van der Geest RJ, et al. Flow assessment through four heart valves simultaneously using 3-dimensional 3-directional velocity-encoded magnetic resonance imaging with retrospective valve tr acking in healthy volunteers and patients with valvular regurgitation. Invest Radiol. 2009;44:669-675.
17. Bastarrika G, Zudaire B, Ferreira M, et al. Assessment of left atrial volumes and function in orthotopic heart transplant recipients by dual- source CT: comparison with MRI. Invest Radiol. 2010;45:72-76.
18. Bhat H, Yang Q, Zuehlsdorff S, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3 T using interleaved echo planar imaging. Invest Radiol. 2010;45:458-464.
19. Frauenrath T, Hezel F, Heinrichs U, et al. Feasibility of cardiac gating free of interference with electro-magnetic fields at 1.5 Tesla, 3.0 Tesla and 7.0 Tesla using an MR-stethoscope. Invest Radiol. 2009;44:539-547.
20. Neizel M, Kramer N, Schutte A, et al. Magnetic resonance imaging of the cardiac venous system and magnetic resonance-guided intubation of the coronary sinus in swine: a feasibility study. Invest Radiol. 2010;45:502-506.
21. Cochet A, Lalande A, Lorgis L, et al. Prognostic value of microvascular damage determined by cardiac magnetic resonance in non ST-segment elevation myocardial infarction: comparison between first-pass and late gadolinium-enhanced images. Invest Radiol. 2010;45:725-732.
22. Elgeti T, Beling M, Hamm B, et al. Cardiac magnetic resonance elastography: toward the diagnosis of abnormal myocardial relaxation. Invest Radiol. 2010;45:782-787.
23. Pediconi F, Catalano C, Roselli A, et al. The challenge of imaging dense breast parenchyma: is magnetic resonance mammography the technique of choice? A comparative study with x-ray mammography and whole-breast ultrasound. Invest Radiol. 2009;44:412-421.
24. Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol. 2009;44:553-558.
25. Carbonaro LA, Verardi N, Di Leo G, et al. Handling a high relaxivity contrast material for dynamic breast MR imaging using higher thresholds for the initial enhancement. Invest Radiol. 2010;45:114-120.
26. Li LP, Ji L, Santos EA, et al. Effect of nitric oxide synthase inhibition on intrarenal oxygenation as evaluated by blood oxygenation leve l-dependent magnetic resonance imaging. Invest Radiol. 2009;44:67-73.
27. Ludemann L, Nafz B, Elsner F, et al. Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent. Invest Radiol. 2009;44:125-134.
28. Gloviczki ML, Glockner J, Gomez SI, et al. Comparison of 1.5 and 3 T BOLD MR to study oxygenation of kidney cortex and medulla in human renovascular disease. Invest Radiol. 2009;44:566-571.
29. Rossi C, Boss A, Artunc F, et al. Comprehensive assessment of renal function and vessel morphology in potential living kidney donors: an MRI-based approach. Invest Radiol. 2009;44:705-711.
30. Zhou X, Bao H, Takakura A, et al. Polycystic kidney disease evaluation by magnetic resonance imaging in ischemia-reperfusion injured PKD1 knockout mouse model: comparison of T2-weighted FSE and true-FISP. Invest Radiol. 2010;45:24-28.
31. Prasad P, Li LP, Halter S, et al. Evaluation of renal hypoxia in diabetic mice by BOLD MRI. Invest Radiol. 2010;45:819-822.
32. Gibbs P, Liney GP, Pickles MD, et al. Correlation of ADC and T2 measurements with cell density in prostate cancer at 3.0 Tesla. Invest Radiol. 2009;44:572-576.
33. Lowry M, Zelhof B, Liney GP, et al. Analysis of prostate DCE-MRI: comparison of fast exchange limit and fast exchange regimen pharmacokinetic models in the discrimination of malignant from normal tissue. Invest Radiol. 2009;44:577-584.
34. Yakar D, Hambrock T, Huisman H, et al. Feasibility of 3T dynamic contrastenhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest Radiol. 2010;45: 121-125.
35. Eyal E, Bloch BN, Rofsky NM, et al. Principal component analysis of dynamic contrast enhanced MRI in human prostate cancer. Invest Radiol. 2010;45:174-181.
36. Kramer NA, Kruger S, Schmitz S, et al. Preclinical evaluation of a novel fiber compound MR guidewire in vivo. Invest Radiol. 2009;44:390-397.
37. Kos S, Huegli R, Hofmann E, et al. Feasibility of real-time magnetic resonance-guided angioplasty and stenting of renal arteries in vitro and in Swine, using a new polyetheretherketone-based magnetic resonance-compatible guidewire. Invest Radiol. 2009;44:234-241.
38. Utting JF, Kozerke S, Luechinger R, et al. Feasibility of k-t BLAST for BOLD fMRI with a spin-echo based acquisition at 3 T and 7 T. Invest Radiol. 2009;44:495-502.
39. Kraff O, Theysohn JM, Maderwald S, et al. High-resolution MRI of the human parotid gland and duct at 7 Tesla. Invest Radiol. 2009;44:518-524.
40. Kraff O, Bitz AK, Kruszona S, et al. An eight-channel phased array RF coil for spine MR imaging at 7 T. Invest Radiol. 2009;44:734-740.
41. Tallantyre EC, Morgan PS, Dixon JE, et al. A comparison of 3T and 7T in the detection of small parenchymal veins within MS lesions. Invest Radiol. 2009;44:491-494.
42. Krug R, Stehling C, Kelley DA, et al. Imaging of the musculoskeletal system in vivo using ultra-high field magnetic resonance at 7 T. Invest Radiol. 2009;44:613-618.
43. Noebauer-Huhmann IM, Szomolanyi P, Juras V, et al. Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. Invest Radiol. 2010;45:554-558.
44. Behrendt FF, Schmidt B, Plumhans C, et al. Image fusion in dual energy computed tomography: effect on contrast enhancement, signal-to-noise ratio and image quality in computed tomography angiography. Invest Radiol.2009;44:1-6.
45. Rist C, Johnson TR, Muller-Starck J, et al. Noninvasive coronary angiography using dual-source computed tomography in patients with atrial fibrillation. Invest Radiol. 2009;44:159-167.
46. Sommer WH, Johnson TR, Becker CR, et al. The value of dual-energy bone removal in maximum intensity projections of lower extremity computed tomography angiography. Invest Radiol. 2009;44:285-292.
47. Morhard D, Fink C, Graser A, et al. Cervical and cranial computed tomographic angiography with automated bone removal: dual energy computed tomography versus standard computed tomography. Invest Radiol. 2009;44: 293-297.
48. Lell MM, Kramer M, Klotz E, et al. Carotid computed tomography angiography with automated bone suppression: a comparative study between dual energy and bone subtraction techniques. Invest Radiol. 2009;44:322-328.
49. Mahnken AH, Bruners P, Schmidt B, et al. Left ventricular function can reliably be assessed from dual-source CT using ECG-gated tube current modulation. Invest Radiol. 2009;44:384-389.
50. Leschka S, Stinn B, Schmid F, et al. Dual source CT coronary angiography in severely obese patients: trading off temporal resolution and image noise. Invest Radiol. 2009;44:720-727.
51. Stolzmann P, Leschka S, Scheffel H, et al. Characterization of urinary stones with dual-energy CT: improved differentiation using a tin filter. Invest Radiol. 2010;45:1-6.
52. Sommer WH, Schenzle JC, Becker CR, et al. Saving dose in triple-rule-out computed tomography examination using a high-pitch dual spiral technique. Invest Radiol. 2010;45:64-71.
53. Kim KS, Lee JM, Kim SH, et al. Image fusion in dual energy computed tomography for detection of hypervascular liver hepatocellular carcinoma: phantom and preliminary studies. Invest Radiol. 2010;45:149-157.
54. Zhang LJ, Peng J, Wu SY, et al. Dual source dual-energy computed tomography of acute myocardial infarction: correlation with histopathologic findings in a canine model. Invest Radiol. 2010;45:290-297.
55. Goetti R, Leschka S, Baumuller S, et al. Low dose high-pitch spiral acquisition 128-slice dual-source computed tomography for the evaluation of coronary artery bypass graft patency. Invest Radiol. 2010;45:324-330.
56. Krissak R, Henzler T, Reichert M, et al. Enhanced visualization of lung vessels for diagnosis of pulmonary embolism using dual energy CT angiography. Invest Radiol. 2010;45:341-346.
57. Schenzle JC, Sommer WH, Neumaier K, et al. Dual energy CT of the chest:how about the dose? Invest Radiol. 2010;45:347-353.
58. Chae EJ, Seo JB, Lee J, et al. Xenon ventilation imaging using dual-energy computed tomography in asthmatics: initial experience. Invest Radiol. 2010; 45:354-361.
59. Thomas C, Krauss B, Ketelsen D, et al. Differentiation of urinary calculi with dual energy CT: effect of spectral shaping by high energy tin filtration. Invest Radiol. 2010;45:393-398.
60. Graser A, Becker CR, Staehler M, et al. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol. 2010;45:399-405.
61. Sommer CM, Schwarzwaelder CB, Stiller W, et al. Dual-energy computedtomography cholangiography in potential donors for living-related liver transplantation: initial experience. Invest Radiol. 2010;45:406-412.
62. Robinson E, Babb J, Chandarana H, et al. Dual source dual energy MDCT: comparison of 80 kVp and weighted average 120 kVp data for conspicuity of hypo-vascular liver metastases. Invest Radiol. 2010;45:413-418.
63. Lell M, Hinkmann F, Anders K, et al. High-pitch electrocardiogram- triggered computed tomography of the chest: initial results. Invest Radiol. 2009;44: 728-733.
64. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis. Invest Radiol. 2010;45:89-95.
65. Tardy I, Pochon S, Theraulaz M, et al. Ultrasound molecular imaging of VEGFR2 in a rat prostate tumor model using BR55. Invest Radiol. 2010;45: 573-578.
66. Anderson CR, Rychak JJ, Backer M, et al. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Invest Radiol. 2010;45:579-585.
67. Guenther F, von zur Muhlen C, Ferrante EA, et al. An ultrasound contrast agent targeted to P-selectin detects activated platelets at supra-arterial shear flow conditions. Invest Radiol. 2010;45:586-591.
68. Fischer T, Thomas A, Tardy I, et al. Vascular endothelial growth factor receptor 2-specific microbubbles for molecular ultrasound detection of prostate cancer in a rat model. Invest Radiol. 2010;45:675-684.
69. Wintersperger BJ, Runge VM, Tweedle MF, et al. Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. Invest Radiol. 2009;44:89-94.
70. Anzidei M, Napoli A, Marincola BC, et al. High- resolution steady state magnetic resonance angiography of the carotid arteries: are intravascular agents necessary? : feasibility and preliminary experience with gadobenate dimeglumine. Invest Radiol. 2009;44:784-792.
71. Hammerstingl R, Adam G, Ayuso JR, et al. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. Invest Radiol. 2009;44:168-176.
72. Hahn G, Sorge I, Gruhn B, et al. Pharmacokinetics and safety of gadobutrolenhanced magnetic resonance imaging in pediatric patients. Invest Radiol. 2009;44:776-783.
73. Ryoo I, Lee JM, Chung YE, et al. Gadobutrol-enhanced, three-dimensional, dynamic MR imaging with MR cholangiography for the preoperative evaluation of bile duct cancer. Invest Radiol. 2010;45:217-224.
74. Chang JM, Moon WK, Cha JH, et al. Dynamic contrast-enhanced magnetic resonance imaging evaluation of VX2 carcinoma in a rabbit model: comparison of 1. 0-M gadobutrol and 0.5-M gadopentetate dimeglumine.Invest Radiol. 2010;45:655-661.
75. Morelli JN, Runge VM, Vu L, et al. Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T. Invest Radiol. 2010;45:810-818.
76. Bauner KU, Reiser MF, Huber AM. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine. Invest Radiol. 2009;44:95-104.
77. Attenberger UI, Runge VM, Jackson CB, et al. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional, gadolinium chelates all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009;44:251-256.
78. Liang J, Sammet S, Yang X, et al. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging. Invest Radiol. 2010;45:233-244.
79. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
80. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (≤2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol. 2010;45:96-103.
81. Ichikawa T, Saito K, Yoshioka N, et al. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrastenhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol. 2010;45:133-141.
82. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol. 2010;45:740-746.
83. Dumas S, Jacques V, Sun WC, et al. High relaxivity magnetic resonance imaging contrast agents. Part 1: impact of single donor atom substitution on relaxivity of serum albumin-bound gadolinium complexes. Invest Radiol. 2010;45:600-612.
84. Jacques V, Dumas S, Sun WC, et al. High-relaxivity magnetic resonance imaging contrast agents. Part 2: optimization of inner- and second-sphere relaxivity. Invest Radiol. 2010;45:613-624.
85. Vymazal J, Spuentrup E, Cardenas-Molina G, et al. Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol. 2009;44:697-704.
86. Alsaid H, De Souza G, Bourdillon MC, et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of ApoE-/- mice: a pilot study. Invest Radiol. 2009;44:151-158.
87. Bazeli R, Coutard M, Duport BD, et al. In vivo evaluation of a new magnetic resonance imaging contrast agent (P947) to target matrix metalloproteinases in expanding experimental abdominal aortic aneurysms. Invest Radiol. 2010; 45:662-668.
88. Katoh M, Haage P, Wiethoff AJ, et al. Molecular magnetic resonance imaging of deep vein thrombosis using a fibrin-targeted contrast agent: a feasibility study. Invest Radiol. 2009;44:146-150.
89. Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74-81.
90. Hope TA, Herfkens RJ, Denianke KS, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. Invest Radiol. 2009;44:135-139.
91. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
92. Bhagavathula N, DaSilva M, Aslam MN, et al. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol. 2009;44:433-439.
93. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol. 2010;45:507-512.
94. Steger-Hartmann T, Hofmeister R, Ernst R, et al. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis. Invest Radiol. 2010;45:520-528.
95. DaSilva M, O'Brien Deming M, Fligiel SE, et al. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol. 2010;45:733-739.
96. Bhagavathula N, Dame MK, Dasilva M, et al. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol. 2010; 45:769-777.